KEYTRUDA® plus INLYTA® - for Renal Cancer
KEYTRUDA® (Pembrolizumab) plus INLYTA® (AXITINIB) - for advanced Renal Cell Carcinoma
Indicated for patients with metastatic Renal Cell Carcinoma regardless of PD-L1 tumor expression. Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis and Nephritis. Continue KEYTRUDA® for a maximum of 24 months. INLYTA® is taken with or without food and should be swallowed whole with a glass of water. Given continuously until progression. Decrease the starting dose by approximately one half for patients with moderate hepatic impairment.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
KEYTRUDA® (Pembrolizumab) IV 200 mg D1 q21 NSS 250 cc 60 minutes
INLYTA® (Axitinib) PO 5 mg BID Daily N/A N/A N/A